Target Price | €63.24 |
Price | €47.08 |
Potential | 34.32% |
Number of Estimates | 23 |
23 Analysts have issued a price target Siemens Healthineers 2026 . The average Siemens Healthineers target price is €63.24. This is 34.32% higher than the current stock price. The highest price target is €78.75 67.27% , the lowest is €50.50 7.26% . | |
A rating was issued by 27 analysts: 23 Analysts recommend Siemens Healthineers to buy, 3 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Siemens Healthineers stock has an average upside potential 2026 of 34.32% . Most analysts recommend the Siemens Healthineers stock at Purchase. |
24 Analysts have issued a sales forecast Siemens Healthineers 2025 . The average Siemens Healthineers sales estimate is €23.8b . This is 1.70% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €25.1b 7.49% , the lowest is €22.9b 2.23% .
This results in the following potential growth metrics:
2024 | €22.4b | 3.15% |
---|---|---|
2025 | €23.8b | 6.34% |
2026 | €24.9b | 4.51% |
2027 | €26.3b | 6.02% |
2028 | €27.8b | 5.61% |
2029 | €29.2b | 4.81% |
2030 | €30.4b | 4.17% |
21 Analysts have issued an Siemens Healthineers EBITDA forecast 2025. The average Siemens Healthineers EBITDA estimate is €4.9b . This is 8.51% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €5.5b 22.42% , the lowest is €4.4b 3.54% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €4.0b | 9.30% |
---|---|---|
2025 | €4.9b | 21.48% |
2026 | €5.4b | 10.13% |
2027 | €5.9b | 9.64% |
2028 | €6.2b | 4.38% |
2029 | €6.7b | 8.76% |
2030 | €7.1b | 6.32% |
2024 | 18.03% | 5.96% |
---|---|---|
2025 | 20.60% | 14.26% |
2026 | 21.70% | 5.34% |
2027 | 22.45% | 3.46% |
2028 | 22.19% | 1.16% |
2029 | 23.02% | 3.74% |
2030 | 23.50% | 2.09% |
24 Siemens Healthineers Analysts have issued a net profit forecast 2025. The average Siemens Healthineers net profit estimate is €2.7b . This is 26.18% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.3b 53.98% , the lowest is €2.6b 17.91% .
This results in the following potential growth metrics and future Net Margins:
2024 | €1.9b | 28.69% |
---|---|---|
2025 | €2.7b | 41.12% |
2026 | €2.9b | 7.14% |
2027 | €3.3b | 12.04% |
2028 | €3.7b | 11.16% |
2029 | €4.0b | 9.15% |
2024 | 8.68% | 24.76% |
---|---|---|
2025 | 11.52% | 32.66% |
2026 | 11.81% | 2.52% |
2027 | 12.49% | 5.76% |
2028 | 13.14% | 5.20% |
2029 | 13.69% | 4.19% |
24 Analysts have issued a Siemens Healthineers forecast for earnings per share. The average Siemens Healthineers EPS is €2.44 . This is 26.42% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.98 54.40% , the lowest is €2.28 18.13% .
This results in the following potential growth metrics and future valuations:
2024 | €1.73 | 29.10% |
---|---|---|
2025 | €2.44 | 41.04% |
2026 | €2.62 | 7.38% |
2027 | €2.93 | 11.83% |
2028 | €3.26 | 11.26% |
2029 | €3.56 | 9.20% |
Current | 24.39 | 15.80% |
---|---|---|
2025 | 19.27 | 21.00% |
2026 | 17.98 | 6.69% |
2027 | 16.05 | 10.73% |
2028 | 14.44 | 10.03% |
2029 | 13.23 | 8.38% |
Based on analysts' sales estimates for 2025, the Siemens Healthineers stock is valued at an EV/Sales of 2.74 and an P/S ratio of 2.20 .
This results in the following potential growth metrics and future valuations:
Current | 2.79 | 10.58% |
---|---|---|
2025 | 2.74 | 1.63% |
2026 | 2.63 | 4.31% |
2027 | 2.48 | 5.68% |
2028 | 2.35 | 5.31% |
2029 | 2.24 | 4.58% |
2030 | 2.15 | 4.01% |
Current | 2.24 | 8.84% |
---|---|---|
2025 | 2.20 | 1.67% |
2026 | 2.11 | 4.32% |
2027 | 1.99 | 5.67% |
2028 | 1.88 | 5.31% |
2029 | 1.79 | 4.58% |
2030 | 1.72 | 4.01% |
Siemens Healthineers...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Sep 11 2025 |
JEFFERIES |
Buy
➜
Buy
|
Unchanged | Sep 10 2025 |
METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
STIFEL EUROPE |
Buy
➜
Buy
|
Unchanged | Aug 15 2025 |
DZ BANK |
Hold
➜
Buy
|
Upgrade | Aug 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Sep 11 2025 |
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Sep 10 2025 |
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Aug 29 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Aug 25 2025 |
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Buy
|
Aug 25 2025 |
Unchanged
STIFEL EUROPE:
Buy
➜
Buy
|
Aug 15 2025 |
Upgrade
DZ BANK:
Hold
➜
Buy
|
Aug 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.